Multiple large-scale meta-analyses have conclusively demonstrated that HER2-positive and TNBC breast cancer exhibit significantly higher sensitivity to NAT compared to other molecular subtypes, a feature intrinsically linked to patient prognosis 19, 20. This evidence concerns the gene BRD2 and breast carcinoma.